Tyvaso and Bile duct obstruction - a phase IV clinical study of FDA data


Bile duct obstruction is reported only by a few people who take Tyvaso.

The phase IV clinical study analyzes which people take Tyvaso and have Bile duct obstruction. It is created by eHealthMe based on reports of 32,955 people who have side effects while taking Tyvaso from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Oct, 03, 2022

32,955 people reported to have side effects when taking Tyvaso.
Among them, 4 people (0.01%) have Bile duct obstruction.

What is Tyvaso?

Tyvaso has active ingredients of treprostinil sodium. eHealthMe is studying from 32,973 Tyvaso users for its effectiveness, alternative drugs and more.

What is Bile duct obstruction?

Bile duct obstruction (blockage in the tubes that carry bile from the liver to the gallbladder) is found to be associated with 1,006 drugs and 557 conditions by eHealthMe.

Number of Tyvaso and Bile duct obstruction reports submitted per year:

Could Tyvaso cause Bile duct obstruction?

Gender of people who have Bile duct obstruction when taking Tyvaso *:

  • female: 100 %
  • male: 0.0 %

Age of people who have Bile duct obstruction when taking Tyvaso *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 50 %
  • 60+: 50 %

Common drugs people take besides Tyvaso *:

  1. Tracleer: 3 people, 75.00%
  2. Xarelto: 1 person, 25.00%
  3. Vitamin D: 1 person, 25.00%
  4. Vitamin B12: 1 person, 25.00%
  5. Treprostinil: 1 person, 25.00%
  6. Spiriva: 1 person, 25.00%
  7. Riociguat: 1 person, 25.00%
  8. Proair Hfa: 1 person, 25.00%
  9. Multivitamin: 1 person, 25.00%
  10. Losartan: 1 person, 25.00%

Common side effects people have besides Bile duct obstruction *:

  1. Transaminases Abnormal: 1 person, 25.00%
  2. Swelling: 1 person, 25.00%
  3. Adverse Drug Reaction: 1 person, 25.00%
  4. Blood Bilirubin Abnormal: 1 person, 25.00%
  5. Breathing Difficulty: 1 person, 25.00%
  6. Cardiac Disorder: 1 person, 25.00%
  7. Chest Pain: 1 person, 25.00%
  8. Cholangitis (infection of the bile duct): 1 person, 25.00%
  9. Chronic Obstructive Pulmonary Disease (a progressive disease that makes it hard to breathe): 1 person, 25.00%
  10. Disease Progression: 1 person, 25.00%

Common conditions people have *:

  1. Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 2 people, 50.00%
  2. Pulmonary Hypertension (increase in blood pressure in the lung artery): 1 person, 25.00%
  3. Cor Pulmonale Chronic (long lasting enlargement of the right ventricle of the heart): 1 person, 25.00%

* Approximation only. Some reports may have incomplete information.

Do you take Tyvaso and have Bile duct obstruction?

Check whether Bile duct obstruction is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Bile duct obstruction and when was it recovered:

Expand to all the drugs that have ingredients of treprostinil sodium:

Alternative drugs to, pros and cons of Tyvaso:

Common Tyvaso side effects:

Browse all side effects of Tyvaso:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Bile duct obstruction treatments and more:

COVID vaccines that are related to Bile duct obstruction:

Common drugs associated with Bile duct obstruction:

All the drugs that are associated with Bile duct obstruction:

Common conditions associated with Bile duct obstruction:

All the conditions that are associated with Bile duct obstruction:

How the study uses the data?

The study uses data from the FDA. It is based on treprostinil sodium (the active ingredients of Tyvaso) and Tyvaso (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: